Johnson & Johnson has received approval from the United States Food and Drug Administration for TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to treat adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The decision follows results from the Phase 3 MajesTEC-3 study showing statistically significant improvements in progression-free survival and overall survival compared with established regimens.

The regulatory milestone matters less because it introduces a new drug and more because it changes where bispecific antibody therapy may be used in the treatment sequence. Teclistamab was previously deployed mainly in later-line settings after several therapies had failed. Moving the drug earlier, in combination with an established anti-CD38 antibody, signals a broader shift in how immunotherapy is being positioned in multiple myeloma care.

The core question now facing clinicians and drug developers is whether bispecific T-cell redirecting therapies can reliably outperform combinations built around proteasome inhibitors and immunomodulatory drugs, which have dominated relapse therapy for more than a decade.

Why moving bispecific antibodies earlier in the treatment sequence could alter relapse management strategies

Multiple myeloma therapy has historically followed a sequential strategy in which patients cycle through combinations of immunomodulators, proteasome inhibitors, and monoclonal antibodies. These regimens often produce strong early responses but gradually lose effectiveness as resistant clones emerge.

Teclistamab belongs to a newer class of therapies known as bispecific antibodies, designed to bring T cells into direct contact with malignant plasma cells. By binding both CD3 on T cells and BCMA on myeloma cells, the therapy redirects immune attack toward the cancer.

Earlier clinical experience positioned these agents primarily as salvage therapies for heavily pretreated patients. Their ability to induce responses in individuals with advanced disease generated excitement, but concerns remained about safety, infection risk, and long-term durability.

The MajesTEC-3 trial challenges the assumption that bispecific antibodies should remain a late-stage option. According to the reported data, teclistamab combined with daratumumab significantly reduced the risk of disease progression or death compared with standard relapse regimens. The hazard ratio reported in the study suggested an 83 percent reduction in risk relative to comparator therapies.

Such a magnitude of benefit, if confirmed in broader clinical practice, would likely push clinicians to consider bispecific combinations earlier in the relapse pathway.

How the MajesTEC-3 trial results reinforce the growing dominance of immune-based therapies in myeloma

The MajesTEC-3 trial represents part of a broader trend in multiple myeloma drug development. Over the past five years, the field has moved rapidly toward immune-mediated therapies including CAR-T cells, antibody-drug conjugates, and bispecific antibodies.

Each approach aims to exploit vulnerabilities in malignant plasma cells that express specific surface markers such as BCMA. The success of BCMA-targeted therapies has been particularly striking. CAR-T products targeting this antigen have demonstrated high response rates in refractory disease, though manufacturing complexity and treatment logistics have limited widespread use.

Bispecific antibodies attempt to capture similar immunologic potency while avoiding the manufacturing delays and infrastructure requirements associated with cellular therapies.

Teclistamab was one of the first BCMA-directed bispecific antibodies to reach regulatory approval, establishing proof of concept for this modality. By pairing the drug with daratumumab, the MajesTEC-3 trial explored whether immune mechanisms could be layered together to enhance anti-tumor activity.

Daratumumab targets CD38 on plasma cells and has become a cornerstone of modern myeloma therapy. Combining it with a BCMA-directed bispecific antibody effectively attacks malignant cells through multiple immune pathways simultaneously.

For clinicians, this raises the possibility that dual-immunotherapy combinations could begin to replace older chemotherapy-based relapse regimens.

What the subcutaneous administration strategy reveals about future treatment delivery models

One aspect of the newly approved regimen that may receive less attention but carries practical importance is the method of drug delivery. Both teclistamab and daratumumab in this regimen are administered subcutaneously.

Subcutaneous administration has become a major focus across oncology drug development because it simplifies treatment logistics. Infusions often require lengthy clinic visits and specialized infrastructure, while subcutaneous injections can potentially be delivered more quickly and in a wider range of settings.

DARZALEX FASPRO incorporates Halozyme Therapeutics’ ENHANZE drug-delivery technology, which enables large-molecule biologics to be delivered beneath the skin rather than through intravenous infusion.

Industry observers note that the shift toward subcutaneous biologics reflects a larger trend toward decentralised cancer care. Shorter administration times may allow more treatments to be delivered in community oncology practices rather than large academic centres.

This logistical advantage could become increasingly important as immunotherapy combinations become more complex and require repeated dosing.

Why the durability of benefit in the MajesTEC-3 study will determine long-term clinical impact

Despite the strong headline results, clinicians will likely examine durability of benefit closely before adopting the regimen broadly.

Multiple myeloma treatments frequently produce impressive early response rates that fade over time. Durable control of disease remains one of the most challenging goals in the field.

The MajesTEC-3 trial reported a three-year progression-free survival rate of 83 percent among patients receiving the teclistamab combination.

If these results translate into sustained remission across a wider patient population, the therapy could meaningfully alter expectations for relapse management. However, real-world data will be needed to determine whether the benefits observed in clinical trials remain consistent in routine practice.

Another factor clinicians will watch is how long patients remain on therapy. Continuous treatment regimens can create cumulative toxicity and adherence challenges, particularly in older populations that make up the majority of myeloma patients.

What safety and infection risks could limit widespread adoption of bispecific antibody regimens

While bispecific antibodies have demonstrated potent anti-tumor activity, they also carry distinct safety concerns.

One of the most widely discussed issues involves infection risk. Because these therapies redirect T cells and alter immune signaling, patients may experience immunosuppression that leaves them vulnerable to opportunistic infections.

Clinical experience with BCMA-targeted bispecific antibodies has already revealed higher rates of infections compared with some traditional therapies. Monitoring strategies, prophylactic antimicrobials, and vaccination protocols may become increasingly important if these drugs move earlier in the treatment pathway.

Cytokine release syndrome is another safety concern. Although typically less severe than with CAR-T cell therapies, the immune activation triggered by bispecific antibodies can still cause fever, hypotension, and other systemic symptoms.

Managing these events requires careful monitoring during early treatment cycles, which may influence how quickly community oncology practices adopt the regimen.

How competition among BCMA-targeted therapies may reshape pricing and access dynamics

The approval also arrives amid intensifying competition in the BCMA therapeutic space.

Several CAR-T cell therapies targeting BCMA have already reached the market, and multiple bispecific antibodies are progressing through late-stage trials. As more agents targeting the same antigen emerge, physicians will face a growing array of treatment options.

This competitive landscape could influence both clinical decision-making and pricing dynamics. If multiple BCMA-directed therapies demonstrate similar efficacy, factors such as administration convenience, toxicity profiles, and cost may play larger roles in determining which regimens become standard practice.

Drug developers are also exploring alternative targets such as GPRC5D and FcRH5, which may eventually expand treatment options beyond BCMA.

What regulators and clinicians will watch next as bispecific therapy expands across earlier treatment lines

The approval of teclistamab with daratumumab represents another step in the ongoing evolution of immunotherapy in multiple myeloma.

Regulatory watchers will likely pay close attention to how bispecific antibodies perform when used earlier in the disease course. Historically, therapies that show strong results in refractory disease do not always maintain the same advantage when introduced sooner.

Another issue involves sequencing. As more immunotherapies become available, clinicians must determine the optimal order in which to deploy them. Using BCMA-targeted therapies earlier could potentially affect the effectiveness of subsequent treatments that rely on the same antigen.

Industry observers believe future trials will increasingly focus on combination strategies involving multiple immune-based mechanisms. The goal will be to achieve deeper responses while avoiding overlapping toxicities.

For the moment, the teclistamab and daratumumab approval reinforces a broader reality in oncology drug development. The field is moving steadily toward immune-directed combinations that attempt to harness multiple biological pathways simultaneously.

Whether this strategy ultimately produces longer survival or simply adds complexity to already crowded treatment algorithms remains an open question that clinicians and regulators will continue to monitor closely.

  BCMA therapy, bispecific antibodies, daratumumab, DARZALEX FASPRO, Halozyme Therapeutics, Johnson & Johnson, MajesTEC-3 clinical trial, multiple myeloma, teclistamab, TECVAYLI